MCK

AI Research

FY2026 EPS guidance raised to $38.05-38.55 + CFO transition → MCK BofA Buy reiterated

McKesson Corporation raised its FY2026 adjusted EPS guidance to $38.05-38.55, above prior consensus estimates, driven by strong pharmaceutical distribution volumes and continued specialty drug growth in oncology and immunology. The company announced a planned CFO transition with Brian Tyler maintaining his CEO role, and Bank of America reiterated its Buy rating citing McKesson's dominant market position in drug distribution serving over 40,000 pharmacies. Key risks include drug pricing legislation that could compress distributor margins and ongoing opioid litigation settlement costs.